Patent protections on semaglutide, the active ingredient in the blockbuster drugs Ozempic and Wegovy, expired Saturday in several key global markets, including India, potentially opening the door to significantly cheaper generic versions of the medications. The expiration covers countries representing roughly 40% of the world’s population, according to the New York Times, including China, Canada, Brazil, Turkey, and South Africa, with India poised for almost immediate availability of generics.
The move is expected to dramatically increase access to the drugs, which have turn into highly sought after for both diabetes management and weight loss. In India, analysts anticipate around 50 generic manufacturers will enter the $60 billion pharmaceutical market within months, potentially creating a market worth approximately $1 billion annually, the BBC reported. This increased competition is projected to drive down monthly costs to around $15, a substantial decrease from current prices that can reach hundreds of dollars.
Public health officials are optimistic that lower prices will enable broader coverage of the medications by national health systems in middle-income countries, extending benefits beyond diabetes treatment to include the prevention of cardiovascular events like heart attacks and strokes. A treatment-access advocate in New Delhi told the New York Times that the availability of these drugs will “democratize” access, moving it away from being limited to high-income countries and wealthy individuals.
Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic and Wegovy, is already responding to the impending competition. The company has reduced prices in India and China, and has pursued legal challenges to defend its patents. Novo Nordisk is similarly reportedly considering strategies to position its branded products as premium options in markets where generic alternatives emerge, according to the New York Times.
The patent expirations come at a challenging time for Novo Nordisk, which faces increasing competition from rival drugs developed by Eli Lilly, as well as the proliferation of compounded versions of semaglutide in the United States. The FDA recently approved a new, higher-dose Wegovy injection, Wegovy® HD, intended to deliver even greater weight loss, PR Newswire reported, signaling Novo Nordisk’s continued investment in its weight-loss portfolio.
However, patients in the United States and most of Europe will likely face a significant wait for more affordable generic options. Patent-term extensions and other regulatory protections mean that generic versions of Ozempic and Wegovy are not expected to become available in those regions until the early 2030s, a delay that critics argue will result in substantial costs for patients and taxpayers.
